Related Experiment Video

Updated: May 31, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Predicting selective drug targets in cancer through metabolic networks

Ori Folger1, Livnat Jerby, Christian Frezza

  • 1The Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel.

Molecular Systems Biology
|June 23, 2011
PubMed

Insights

Researchers developed a genome-scale cancer metabolism model to identify new drug targets. This model predicts 52 cytostatic targets and synergistic drug combinations, aiding personalized cancer therapy development.

Area of Science:

  • Metabolic reprogramming in cancer
  • Computational systems biology
  • Cancer drug discovery

Background:

  • Cancer cells exhibit altered metabolic pathways crucial for their growth and survival.
  • Identifying novel therapeutic targets within cancer metabolism is a key research area.
  • Genome-scale models offer a powerful approach to understanding complex biological systems.

Purpose of the Study:

  • To develop the first genome-scale network model of cancer metabolism.
  • To identify essential genes for cancer cell proliferation.
  • To predict novel cytostatic drug targets and synthetic lethal drug combinations for cancer therapy.

Main Methods:

  • Construction and validation of a genome-scale metabolic network model for cancer.
  • In silico prediction of essential genes and drug targets.
  • Analysis of drug synergy using gene expression and drug efficacy data (NCI-60).
  • Integration of gene expression downregulation and somatic mutations for personalized treatment strategies.

Main Results:

  • The model successfully identified genes essential for cancer cell proliferation.
  • 52 cytostatic drug targets were predicted, with 40% being novel.
  • Synergistic effects of predicted synthetic lethal drug combinations were validated.
  • Potential selective treatments tailored to specific cancer types were identified.

Conclusions:

  • The developed genome-scale model is a valuable tool for understanding cancer metabolism and predicting therapeutic targets.
  • The findings highlight the potential of targeting metabolic vulnerabilities in cancer.
  • This approach facilitates the discovery of new anticancer drugs and personalized treatment strategies.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...